EcoDrugPlus

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSSPAG00000007489
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSSPAG00000010211
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSSPAG00000011815
Gene Symbol: LOC103355171
4 Cross references
257 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b-Like

Ensembl ID : ENSSPAG00000021903
Gene Symbol: LOC103368197
4 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSSPAG00000016922
Gene Symbol: INPP5D
3 Cross references
215 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSSPAG00000012933
Gene Symbol: INSR
3 Cross references
212 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSSPAG00000005776
Gene Symbol: INSR
2 Cross references
211 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSSPAG00000011101
Gene Symbol: LOC103374774
3 Cross references
211 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSSPAG00000007089
Gene Symbol: LOC103359504
3 Cross references
203 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSSPAG00000020066
Gene Symbol: LOC103364747
3 Cross references
186 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSSPAG00000012068
Gene Symbol: LOC103358513
3 Cross references
182 Possible Orthologues:

Integrin Alpha-5-Like

Ensembl ID : ENSSPAG00000019165
Gene Symbol: LOC103365860
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).